See why these three stocks missed out on the broader market's rise on Tuesday.
News & Analysis: Bayer AG (ADR)
The falling costs of genomic sequencing have led to exponential growth in synthetic biology. Ginkgo Bioworks' Chief Commercial Officer shares a few things investors should know about this fast-growing field.
Next-generation biotech products could threaten the existence of agricultural nutrient producers, but few seem to be taking notice.
Companies across the agricultural value chain are investing in digital tools to help farmers. Here are three to put on your radar.
A $289 million dollar verdict by a California jury could mean Bayer's on the hook for billions in damages tied to Roundup.
The company's pending acquisition faces an uncertain road to approval, which presents unique risks to investors.
Low commodity prices have led to a wave of consolidation in agricultural industries. This year could make or break $186 billion in deals.
It's hard to figure out what's real and what's political grandstanding, but this is what some major players are promising.
Looking for Big Pharma bargains? Mallinckrodt, Bayer, and Bristol-Myers Squibb might be right up your alley.
Licensing a next-generation gene editing tool called CRISPR could greatly reduce time to market for future agricultural products and save the company hundreds of millions of dollars in expenses.